The high-galectin-3 group (n = 10) showed a poorer prognosis than the low-galectin-3 group (n = 11) in pancreatic cancer patients (p = 0.006) [29], and 2), PLAU upregulation was associated with the basal type of PDAC, and an increased PLAU protein expression was associated with poor prognosis (P = 0044), and within the basal subtype, the clinical outcome in the high PLAU expression group is significantly worse than the low PLAU expression group (P = 0.018) [30]. This evidence concerns the gene PLAU and familial pancreatic carcinoma.